BlackRock
SER icon

BlackRock’s Serina Therapeutics SER Stock Holding History

BlackRock’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.61K Sell
2,378
-55,886
-96% -$105K ﹤0.01% 5497
2026
Q1 		$113K Buy
58,264
+41,015
+238% +$90.3K ﹤0.01% 4932
2025
Q4 		$33K Buy
17,249
+4,127
+31% +$16.7K ﹤0.01% 5133
2025
Q3 		$70.3K Buy
13,122
+1,349
+11% +$7.18K ﹤0.01% 4917
2025
Q2 		$72.5K Buy
11,773
+8,706
+284% +$49.5K ﹤0.01% 4911
2025
Q1 		$17.4K Sell
3,067
-505
-14% -$2.39K ﹤0.01% 5109
2024
Q4 		$17.9K Hold
3,572
– – ﹤0.01% 5116
2024
Q3 		$23.9K Sell
3,572
-406
-10% -$3.22K ﹤0.01% 4918
2024
Q2 		$38.1K Buy
3,978
+448
+13% +$4.41K ﹤0.01% 4913
2024
Q1 		$47.5K Sell
3,530
-4
-0.1% -$56 ﹤0.01% 4881
2023
Q4 		$47.9K Sell
3,534
-218
-6% -$4.01K ﹤0.01% 4975
2023
Q3 		$89.7K Buy
3,752
+3
+0.1% +$79 ﹤0.01% 4876
2023
Q2 		$118K Buy
3,749
+1
+0% +$21 ﹤0.01% 4865
2023
Q1 		$87.4K Sell
3,748
-4
-0.1% -$92 ﹤0.01% 4987
2022
Q4 		$72.8K Sell
3,752
-5
-0.1% -$105 ﹤0.01% 5134
2022
Q3 		$74K Sell
3,757
-206
-5% -$4.66K ﹤0.01% 5264
2022
Q2 		$80K Sell
3,963
-1,537
-28% -$41.5K ﹤0.01% 5300
2022
Q1 		$165K Sell
5,500
-83
-1% -$2.36K ﹤0.01% 5156
2021
Q4 		$214K Buy
5,583
+57
+1% +$1.54K ﹤0.01% 5092
2021
Q3 		$183K Sell
5,526
-30
-0.5% -$1.26K ﹤0.01% 5003
2021
Q2 		$303K Buy
5,556
+1,246
+29% +$62.5K ﹤0.01% 4805
2021
Q1 		$245K Buy
4,310
+13
+0.3% +$910 ﹤0.01% 4710
2020
Q4 		$230K Buy
4,297
+7
+0.2% +$403 ﹤0.01% 4461
2020
Q3 		$123K Sell
4,290
-31
-0.7% -$1.11K ﹤0.01% 4487
2020
Q2 		$144K Sell
4,321
-28,195
-87% -$830K ﹤0.01% 4432
2020
Q1 		$1.06M Sell
32,516
-736
-2% -$34.6K ﹤0.01% 3853
2019
Q4 		$2.13M Buy
33,252
+144
+0.4% +$7.78K ﹤0.01% 3771
2019
Q3 		$2.28M Buy
33,108
+913
+3% +$86.6K ﹤0.01% 3708
2019
Q2 		$4.16M Buy
32,195
+15,549
+93% +$2.11M ﹤0.01% 3580
2019
Q1 		$2.37M Sell
16,646
-563
-3% -$82.3K ﹤0.01% 3646
2018
Q4 		$1.81M Buy
+17,209
New +$2.19M ﹤0.01% 3711

Other funds holding SER

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AWE
Avidian Wealth Enterprises Houston, Texas $3.62B AUM 24.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PSB
Piscataqua Savings Bank Portsmouth, New Hampshire $148M AUM 32.61% 1-Year Est. Return

BlackRock's SER Position: Q2 2026 in Review

BlackRock reduced its Serina Therapeutics (SER) stake by 96% in Q2 2026, selling an estimated $105K and leaving 2,378 shares worth $4.61K. The position accounts for ﹤0.01% of the portfolio, ranked #5497.

BlackRock first reported a position in SER in Q4 2018 and has held it in 31 quarters since. The position peaked at $4.16M in Q2 2019. 21 funds tracked by Wall St. Rank hold SER as of Q2 2026.

  • BlackRock held 2,378 shares of Serina Therapeutics worth $4.61K as of Q2 2026.
  • BlackRock sold 55,886 Serina Therapeutics shares in Q2 2026, an estimated $105K.
  • Serina Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5497 holding.
  • BlackRock first reported a position in Serina Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • BlackRock's Serina Therapeutics position peaked at $4.16M in Q2 2019.
  • 21 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.